Navigation Links
ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
Date:8/6/2008

Company expands beyond core business of discovery and safety services to meet the evolving needs of the drug discovery and development community

BOSTON and CLEVELAND, Aug. 6 /PRNewswire/ -- ChanTest, the world-leading provider of validated ion channel-expressing cell lines and services for drug-discovery and development applications, will make a selection of its fully validated cell lines available to researchers through a new Web site: http://www.chantestchannels.com. ChanTest Founder and CEO Arthur ("Buzz") Brown announced the new business offering today at the Drug Discovery & Development Innovative Technologies conference in Boston. ChanTest's initial launch will be of nine cell lines that the company has validated on the major ion channel platforms, including manual patch clamp, PatchXpress(R), QPatch, IonWorks(R), Quattro(TM), and FLIPR-Tetra(R). Optimization on all platforms is in progress. According to Dr. Brown, the company will expand the number of cell lines available during 2008 to 64.

"As the preeminent ion channel company, our goal is to serve all the ion channel needs of pharmaceutical and biotech customers -- from early functional screens for profiling drug candidates or ranking within profiles during the drug-discovery process -- to a complete set of in vitro GLP service products for cardiac risk assessment," said Dr. Brown. "However, some companies prefer to maintain testing in house. For those customers, we're pleased to offer a new way that researchers can benefit from ChanTest's ion channel expertise and exhaustive study of the characteristics of our ion channel library -- by purchasing our validated cell lines. We want to ensure that all researchers have the best opportunity to identify ion channels as pharmaceutically relevant targets and accelerate work on providing new drugs to those targets."

The nine initial validated cell lines available currently include the following:

Channel: hERG hERG KvLQT1-MinK Kir2.1 Kv1.5

Cell Type: HEK293 CHO CHO HEK293 HEK293

Channel: Kv4.3 HCN4 Nav1.7 Kv1.3

Cell Type: HEK293 HEK293 CHO HEK293

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines -- the most comprehensive in the world. Since its inception in 1998, ChanTest has tested some 20,000 compounds for approximately 400 global pharmaceutical and biotech companies -- helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. The company also offers a selection of its validated cell lines directly to customers for use in their internal research. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit http://www.chantest.com.


'/>"/>
SOURCE ChanTest
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839
2. ChanTest Launches Redesigned Web Site
3. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
4. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
5. Ingenuity Systems Launches Analysis Services
6. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
7. iNutrition Launches New Fission Fruit Nutrition Bars
8. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Ranbaxy Launches Omeprazole 40 mg Capsules
11. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseq™ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... closer look at four equities in the Biotech industry: ... EYEG), Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus ... March 21 st , 2017, Credit Suisse upgraded its rating ... stocks by downloading their free report at: ...
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
Breaking Biology Technology:
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
Breaking Biology News(10 mins):